Biovica receives order worth one million SEK for evaluation of new cancer drugs

2017-05-04 10:00

Uppsala, Sweden, May 4 2017. Biovica has received an order for the company's product DiviTum® from a global contract research company (CRO company), commissioned by a global pharmaceutical company to study the effectiveness of new cancer drugs.

The value of the order is approximately one million SEK . The order is one of several from the same customer and so far, the second largest Biovica has received.

"We are very pleased that leading actors in the industry see the value of our product and use DiviTum® in their evaluation of new drugs. This is in line with our ambition to participate in the development of new cancer drugs and to contribute to the best possible treatment outcome for cancer patients. ", says Anders Rylander, CEO Biovica.

>4,500

Numbers of patients in studies

28

Publications

19

Pharma Projects

Are you a US resident?

Only US residents will be able to qualify for this program

No